10x Genomics (TXG) Sees Strong Early Orders for New Atera Platform
10x Genomics (NASDAQ:TXG) reported Q2 revenue of $151m, including a $1.6m Takara settlement; excluding it, revenue was $149.4m, up 3% YoY. Atera booked orders already exceed planned 2026 shipments (~40 units). Cash rose to $552m and gross margin to 74%. Full-year revenue guidance raised to $610m-$630m; instrument revenue fell 47% YoY.
How this was made
The 30-second read
Why it matters
The key trade setup is balancing strong Atera demand and raised full-year revenue guidance against a guided near-term instrument revenue decline and shipment build constraints.
Market read
Atera order strength and raised guidance are supportive, but the guided Q3 instrument revenue step-down and shipment constraints can drive near-term volatility.
What to watch
Instrument revenue decline is large and management expects a sequential step-down in Q3, so traders may focus more on the near-term revenue mix than on order backlog.
Background
10x reported Q2 results and highlighted the launch of Atera, including order momentum, consumables growth, and guidance changes.
Ticker impact
10x says booked orders for its new Atera platform already exceed full-year 2026 planned shipments, while raising full-year revenue guidance to $610M-$630M.
Bias toward near-term upside on order and guidance strength, with volatility risk from the guided sequential instrument revenue step-down into Q3.
The article provides multiple concrete positives (Atera booked orders, consumables growth, margin expansion, raised guidance) alongside concrete negatives (instrument revenue down ~47% YoY, expected sequential step-down in Q3, shipment build constraint).
Market effects
Signals continued demand shift from older spatial/Chromium instruments toward a new platform, which can re-rate instrument-cycle expectations for single-cell/spatial workflows.
APAC weakness is attributed to China purchase timing ahead of anticipated tariffs, implying regional demand timing risk rather than structural collapse.
Oncology biomarker partnerships and clinical-diagnostics positioning may attract longer-duration capital to single-cell platform ecosystems.
Counterpoint
Booked Atera orders exceeding planned shipments may reflect backlog timing, while management’s continued ~40-unit shipment target suggests near-term revenue recognition may lag demand.
Key entities
- company10x Genomics
NASDAQ-listed single-cell and spatial genomics platform company launching the Atera instrument platform.
- product_platformAtera
New 10x instrument platform with booked orders exceeding full-year 2026 planned shipments.
- research_partnerCleveland Clinic
New research partnership mentioned for oncology biomarker work tied to treatment response.
- research_partnerLausanne University Hospital
New research partnership mentioned for oncology biomarker work tied to treatment response.
- counterpartyTakara
Settlement payment referenced as boosting Q2 revenue comparability.
